Disclaimer
Please read this page before proceeding further. By clicking to log into this site, you are agreeing that you have reviewed and agreed on the terms and conditions contained herein.
This website is not intended for the general public. It is designed for use by Professional clients and other eligible counterparties as defined under Maltese Regulations. You must agree to the terms and conditions set forth below for your own behalf and for all others, on whose behalf you access the Company website and acquire information about Fund Scouting & Advisory Limited (“the Company”). The Company is licensed by the Malta Financial Services Authority to provide investment services as a Category 1b in terms of the Investment Services Act (1994) and is also authorized to provide its services in Italy and Luxembourg.
Access subject to local restrictions
This website and the information which is contained in it or otherwise incorporated by reference has not been and will not be submitted to, become approved by or verified by or registered with any relevant regulatory authorities under local laws. This website is not intended for and should NOT be accessed by persons who are located or resident in any jurisdiction where (by reason of that person’s nationality, domicile, residence or otherwise) the publication or availability of this website is prohibited or contrary to local law or regulation or which would subject the Company to any registration or licensing requirements in such jurisdiction.
The information found on this website should not be circulated or distributed to any person other than to any professional investors or eligible counterparties (as defined in local laws and regulations), and should not be relied upon by any other persons or redistributed to the retail public in relevant countries.
No Offer or Solicitation
The information contained and referenced on this website (including without limitation the information, functions and documents herein (hereinafter referred to as the “Contents”) is supplied solely for information purposes only and should not be regarded as an offer, solicitation or recommendation for any investments, investment funds or products in any jurisdiction where such activity is unlawful. The Contents have been prepared without taking into consideration the investment objectives, financial situation or means of any person or entity and the website is not soliciting any action based upon them. The Contents are not to be construed as a recommendation or an offer or invitation to trade in any units of funds nor should any Contents form the basis of, or be relied upon in connection with, any contract or commitment on the part of any person to proceed with any transaction. The Contents are not to be construed as soliciting or promoting any financial products or services. This website is not directed at you, if we are prohibited by any law or regulation of any jurisdiction from making the information on this site available to you and is not intended for any use which would be contrary to local law or regulation. In particular, the Contents of this website are not aimed at the dissemination in the United States of America or to U.S. citizens, in ways other than in accordance with U.S. Laws. If you are visiting our web site from any such jurisdiction, please kindly disconnect from our web pages.
No Warranty
The Contents are published in good faith. No advice, representation or warranty, express or implied is made by the Company or by any person as to its adequacy, accuracy, completeness, reasonableness or that it is fit for your purpose and it should not be relied on as such. Every effort has been made to ensure the accuracy of the Contents, but it may be based on outdated data or subject to errors. Furthermore, you must acknowledge that past performance is not indicative of future performance. The price of investment instruments can go down as well as up and may be affected by changes in rates of exchange. An investor may not get back the amount invested. Any investments may involve significant risks. Whilst it is the intention of the Company to provide the right investment advice, there can be no assurance that these investments will be successful. It is possible that an investor may lose a substantial proportion or all of its investment. As a result, each investor should carefully consider whether it can afford to bear the risks of conducting its investment. Investors should read the offering documents for further details including the risk factors before making an investment.
No Tax or Legal Advice
Potential investors should inform themselves as to (a) the possible tax consequences, (b) the legal requirements and (c) any foreign exchange restrictions or exchange control requirements which they might encounter under the laws of the countries of their citizenship, residence, incorporation or domicile and which might be relevant to the subscription, holding, or disposal of any units of investments. It is the responsibility of any persons in possession of any marketing material or any documentation with respect to any instrument or security and any persons wishing to apply for services, for their own purposes or on behalf of others, to inform themselves of, and to observe and comply with, all applicable laws and regulations of any relevant jurisdiction. Prospective investors should inform themselves as to the legal requirements of so applying and any applicable exchange control requirements and taxes in the countries of their nationality, residence or domicile. Statements made in any documents, except where otherwise stated, are based on the law and practice currently in force of the respective jurisdiction and are subject to changes therein.
If you are unsure about the meaning of any information provided, please consult your financial or other professional adviser.
No Liability
The Company shall have no liability for any loss or damage arising in connection with this website or out of the use, in ability to use or reliance on the Contents by any person, including without limitation, any loss of profit or any other damage, direct or consequential, regardless of whether they arise from contractual or tort (including negligence) or whether the Company has foreseen such possibility, except where such exclusion or limitation contravenes the applicable law. By accessing certain links on this website, you may leave this website. The Company has not examined any of the linked websites and does not assume any responsibility for the contents of such websites, nor the services, products or items offered through such websites.
In order to proceed and access more information you must confirm that you have read, fully understood and accept the terms as defined above by clicking the “AGREE” button below.
I agree
Overview
Bellevue Asia Pacific Healthcare
The fund’s aim is to achieve capital growth in the long term. The BB Adamant Asia Pacific Healthcare Fund invests in healthcare stocks of companies that have their registered office or carry out the majority of their economic activity in the healthcare markets of the Asia-Pacific region. Its investment universe consists of generics producers, pharma and biotechnology companies, medical technology and services firms. Experienced sector specialists focus on profitable companies that have a well-established product portfolio. Investments are made based on fundamental research analysis. Stock selection is exclusively bottom up, independent of benchmark weightings.
-
Strategy:Healthcare equity
-
AUM (€m):
301
-
Management fee:0.90%
-
ESG:SFDR art.8
-
Currencies (I class):EUR, USD, CHF
-
Platform:Allfunds
Update: April 2023
Bellevue Medtech & Services
The fund’s aim is to achieve capital growth in the long term. The fund invests worldwide in companies active in the medical technology and healthcare services sector. Aim is to provide investors an attractive Healthcare Fund solution by investing in the entire healthcare universe with the exclusion of drug makers. Experienced sector specialists focus on profitable, liquid mid and large cap companies with an established product portfolio as well as fast growing small cap companies with leading-edge technology offering. Stock selection is based on fundamental company analysis, focusing in particular on the medical benefits and the potential savings for the healthcare system as well as the expected market potential of a company’s products and services.The selection of the portfolio companies is entirely bottom up, independent of benchmark weightings.
-
Strategy:Healthcare equity
-
AUM (€m):
1643
-
Management fee:0.90%
-
ESG:SFDR art.8
-
Currencies (I class):EUR, USD, GBP, CHF
-
Platform:Allfunds
Update: April 2023
Bellevue Global Macro
The fund’s objective is to generate consistent absolute returns of 5-7% p.a. in any market environment with an annualized volatility around 5-7%. The fund actively invests globally in several asset classes with the possibility to build up long and short exposure, maintaining a constant level of risk over time. A proprietary global macro screening engine supports an experienced team of specialists to express their market views and to define the most successful top down strategies. Risk is an integrated part within the entire investment process. By targeting an explicit risk level on a daily basis the risk profile is maintained over time. The portfolio is mainly invested in liquid assets,the Fund offers daily liquidity.
-
Strategy:Absolute return
-
AUM (€m):
112
-
Management fee:0.80%
-
ESG:SFDR art.8
-
Currencies (I class):EUR, USD, GBP, CHF
-
Platform:Allfunds
Update: April 2023
Bellevue Digital Health
The fund’s aim is to achieve capital growth in the long term. The fund invests globally at least two thirds of the portfolio in companies whose business activities have a strong focus on the digitalization of the healthcare sector. A global network of experts spanning scientific and industrial fields support the Management Team in forming opinions. The selection of portfolio companies is bottom-up.
-
Strategy:Healthcare equity
-
AUM (€m):
677
-
Management fee:0.90%
-
ESG:SFDR art.8
-
Currencies (I class):EUR, USD, CHF
-
Platform:Allfunds
Update: April 2023
Bellevue Emerging Markets Healthcare
The fund’s aim is to achieve capital growth in the long term. The fund invests in companies that have their registered office or carry out the majority of their economic activity in the healthcare markets of emerging countries. Its investment universe consists of generics producers, pharma and biotechnology companies, medical technology and services firms. Experienced sector specialists focus on profitable companies that have a wellestablished product portfolio. Investments are made based on fundamental research analysis. Stock selection is exclusively bottom-up, independent of benchmark weightings.
-
Strategy:Healthcare equity
-
AUM (€m):
72
-
Management fee:0.90%
-
ESG:SFDR art.8
-
Currencies (I class):EUR, USD, CHF
-
Platform:Allfunds
Update: April 2023
Bellevue Sustainable Healthcare
The fund’s aim is to achieve capital growth in the long term. The BB Adamant Sustainable Healthcare Fund invests in healthcare firms with strong sustainability credentials and innovative business models. Examples of sustainability in the healthcare industry are environmentally sound procurement policies for drug makers, high safety standards for medical products and services, and a commitment to ethics when conducting clinical trials. From the perspective of the patient, the early diagnosis of life-threatening diseases, personalized medicine enabling highly selective treatments and efficient treatment procedures are key sustainability indicators. A variety of high-growth themes, smart stock selection using our established investment process and the application of sustainability criteria are the fund’s tools for achieving attractive returns.
-
Strategy:Healthcare equity
-
AUM (€m):
189
-
Management fee:0.90%
-
ESG:SFDR art.8
-
Currencies (I class):EUR, USD, CHF
-
Platform:Allfunds
Update: April 2023
Bellevue Biotech
The fund’s aim is to achieve capital growth in the long term. The Fund invests worldwide in companies active in the biotechnology sector. Experienced sector specialists focus on profitable mid and large cap companies with an established product portfolio. Stock selection is based on fundamental analysis, in particular of the medical indications addressed, the means of efficacy and the market potential. A global network of experts spanning scientific and industrial fields supports the Management Team in forming opinions and making investment decisions. The selection of portfolio companies is entirely bottom-up, independent of benchmark weightings.
-
Strategy:Biotech equity
-
AUM (€m):
57
-
Management fee:0.90%
-
ESG:SFDR art.8
-
Currencies (I class):EUR, USD, GBP, CHF
-
Platform:Allfunds
Update: April 2023
News
| Date | Title | Abstract | Link |
|---|---|---|---|
21.03.2023 | Biotech Sector To Take Off In 2023 | Dr. Daniel Koller from Bellevue Asset Management talks to Wealth Briefing about the buying opportunity being created by low valuations in the biotech sector. | Read more |
21.02.2023 | Emerging Markets Healthcare sector comeback | Fundamental factors are indicating that the recent advance by healthcare stocks across the Asia-Pacific region and in emerging market countries is solidifying into a sustained recovery.
Read the market commentary from Remo Krauer Senior Portfolio Manager Healthcare Funds & Mandates at Bellevue AM. | Read more |
26.01.2023 | Regional healthcare strategies: China in focus | After years of uncertainty, the Chinese healthcare market is expected to grow by around 10% again in 2023. Valuations are currently extremely attractive following Oliver Kubli and Remo Krauer, Portfolio Managers of Bellevue Asia Pacific and Emerging Markets Healthcare. | Watch here |
25.01.2023 | Five opportunities for healthcare investors | Bellevue Asset Management casts a spotlight on five major trends in the healthcare sector for 2023 and outlines their potential from an investor’s perspective.
| Read more |
09.01.2023 | Interesting news on FDA approval could boost bellevue biotech fund | Exciting updates on the FDA approval of Biogen's Alzheimer's drug could herald a new era in Alzheimer's research.
What effects will this news have on the thematic fund, specialized in biotechnology, Bellevue Biotech?
| Read more |
16.11.2022 | Healthcare Investments in East & West - Talking with Cyrill Zimmermann, Head Healthcare Funds | Investing in Healthcare in the East & West: in this video, Dr. Cyrill Zimmermann, head of Healthcare funds at Bellevue Asset Management, delves into the topic of the healthcare sector in light of what is happening in the US and China.
| Read more |
25.10.2022 | Why China is persisting with its zero-covid policy? | Paul Major, Portfolio Manager of the Bellevue Healthcare Trust, returns to the Art of Investment Podcast this week to discuss a host of health-related topics including how healthcare systems need to change following the pandemic and why he prefers small and medium size companies compared to large, mega cap businesses.
| Read more |
04.10.2022 | Bellevue Biotech – News on Alzheimers | Last week Eisai/Biogen presented their highly anticipated data of their product candidate to treat Alzheimer’s dementia. Is this the long awaited breakthrough many have been hoping for or just data that triggers again more questions than answers?
| Read more |
01.09.2022 | Medtech & Services sector lives up to its reputation - comment by Marcel Fritsch | Sector rotation into value has lost considerable momentum and investors are showing more interest in fast-growing, innovative, non-cyclical stocks. This has put medtech & services companies (back) on the radar of the general investment community.
| Read more |
08.08.2022 | Bellevue Managers confident future of global healthcare industry is bright one | Here is the latest article in the Mail on Sunday mentioning Bellevue Healthcare Trust from "This is Money UK".
| Read more |
20.07.2022 | Bellevue Healthcare Strategy – GARP poised for a comeback | The fund's PEG ratio (price/earnings ratio relative to earnings growth) has never been as low as it is now. That is a sign of fair valuations and enticing investment opportunities. Samuel Stursberg explains why the time is ripe for a comeback by profitable growth companies and how the portfolio will benefit from it.
| Read more |
05.07.2022 | 2022's historic opportunities for healthcare investors | Paul Major, portfolio manager for Bellevue Healthcare Trust (BBH.L) joined Richard Kimberley at Kepler Trust Intelligence to discuss how the strategy is looking to take advantage of recent volatility, in what he says is likely to be remembered as a historic buy opportunity for investors.
| Read more |
22.06.2022 | Emerging Markets Healthcare – Remo Krauer Update | Recent quarterly figures and outlooks of many Asian healthcare companies remain robust and encouraging, despite ongoing political and macroeconomic uncertainties. Remo Krauer, PM of the Bellevue Emerging Market Healthcare fund, explains background and impact of the current developments.
| Read more |
14.06.2022 | Are we living in a post-Covid world? Listen to the podcast with Paul Major, PM of the Bellevue Healthcare Trust. | Paul Major of Bellevue Healthcare Trust and Covid-19 researcher and oncologist Prof. Justin Stebbing, discuss the ongoing transition to a post-Covid-19 world.
| Read more |
08.06.2022 | Can we benefit from the diverse characteristics of the healthcare sector? | In this interview, Dr. Terence McManus outlines the investment strategy of the new Bellevue Diversified Healthcare Fund.
| Read more |
31.05.2022 | Has the pandemic reshaped the Healthcare sector? | Paul Major of the Bellevue Healthcare Trust tells to The Daily Telegraph how the pandemic made doctors more willing to try new approaches to care.
| Watch here |
17.05.2022 | Biotech sector sees potential for growth post Covid | In this article from Wealthadviser, Dallas Webb, Portfolio Manager of the Bellevue BB Biotech fund analyses opportunities in the Biotechnology sector.
| Watch here |
27.04.2022 | Is normalization of surgery volumes positive for medtech companies? Here the answer from Marcel Frisch | Normalization of surgery volumes is positive for medtech companies and US health insurers are benefitting in an environment of rising interest rates. Marcel Fritsch, Portfolio Manager of the Bellevue Medtech & services fund, discusses the current year and the investment strategy.
| Watch here |
26.04.2022 | Digital Health: encouraging company specific news flow – Stefan Blum talks about the Bellevue Digital Health fund | Encouraging company specific news flow, lower valuation multiples and challenges around healthcare workforce are positive factors for the digital health investment case. Stefan Blum, Portfolio Manager of the Bellevue Digital Health fund, discusses the current year and the investment strategy. | Watch here |
21.04.2022 | Bellevue’s Paul Major: investing to solve healthcare problems | In this article Paul Major tells Mary McDougall why there is a “tremendous buying opportunity” in small and mid caps. | Read more |
13.04.2022 | Underestimated newcomers – Bellevue commentary on the mid-cap Biotech companies | The steadily growing importance of small and mid-cap biotech companies with innovative product pipelines has not yet been fully acknowledged by financial markets.
Here’s the market commentary by Dr. Daniel Koller.
| Read more |
06.04.2022 | China’s Healthcare industry at a turning point | Remo Krauer, Senior Portfolio Manager of the Bellevue Healthcare Asia Pacific fund, shares his point of view concerning the Healthcare industry in China, which recently made further significant progress in terms of quality and its international profile.
| Read more |
05.04.2022 | Digitization of the healthcare sector | Stefan Blum, portfolio manager of the Bellevue Digital Health Fund, provides in-depth insights into the topic of digitization in healthcare.
| Read more |
01.06.2021 | Livestream Digital Health - Revolution in Healthcare | Marcel Fritsch and Stefan Blum, the Co-Lead portfolio managers of the BB Adamant Digital Health (Lux) fund, present a livestream on the topic of "Digital Health - Revolution in Healthcare". | Watch here |
18.02.2021 | BB Insights Video Update - Medtech & Services - February 2021 | Marcel Fritsch and Stefan Blum, portfolio managers of the BB Adamant Medtech & Services and BB Adamant Digital Health review the market situation, new opportunities and some of the companies best positioned to navigate the current uncertainty caused by the pandemic. | Watch |
14.01.2021 | Bellevue looks back on 2020 | Product specialists Markus Peter, Jean-Pierre Gerber and Loreno Ferrari look back on 2020 and explain what impact the corona crisis had on Bellevue's investment strategies and in which areas there is potential for 2021. | Read More |
28.11.2020 | Winning the digital health race | In the attached article Marcel Fritsch, portfolio manager of Bellevue's BB Adamant Digital Health Fund, proposes an analysis of the main growth drivers in the booming digital health sector. | Read More |
27.08.2020 | A new digital healthcare giant? | Stefan Blum, Portfolio Manager of the Adamant Global Medtech and Services e BB Adamant Digital Health funds discusses a recent acquisition which could represent an opportunity for the American merket and investors. | Read More |
© 2023 - Fund Scouting & Advisory Ltd - All rights reserved
-
Full name of legal entity:
Fund Scouting & Advisory Limited
-
Reg. number:
C89570 -
Address:
6 Market Street, Floriana FRN1082, Malta -
Phone:
-
Fax:
-
E‐mail:
-
Linkedin: